Sugi Predict

Sugi Predict / Compounds / SCHEMBL2148753

SCHEMBL2148753

SCHEMBL2148753

CCOC(=O)c1cc(C)c[nH]1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GABRP O00591 1/20 0.51
▸ GABRD O14764 1/20 0.51
▸ GABRA1 P14867 1/20 0.51
▸ GABRB1 P18505 1/20 0.51
▸ GABRG2 P18507 1/20 0.51
▸ GABRB3 P28472 1/20 0.51
▸ GABRA5 P31644 1/20 0.51
▸ GABRA3 P34903 1/20 0.51
▸ GABRA2 P47869 1/20 0.51
▸ GABRB2 P47870 1/20 0.51
▸ GABRA4 P48169 1/20 0.51
▸ GABRE P78334 1/20 0.51
▸ GABRA6 Q16445 1/20 0.51
▸ GABRG1 Q8N1C3 1/20 0.51
▸ GABRG3 Q99928 1/20 0.51
▸ GABRQ Q9UN88 1/20 0.51
▸ ALDH1A1 P00352 7/20 0.49
▸ KDM4E B2RXH2 4/20 0.49
▸ HPGD P15428 3/20 0.49
▸ RAB9A P51151 3/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16453472 0.83 CA12 (0.52) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL2518047 0.83 BAZ2B (0.56) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL14791060 0.83 GABRA1 (0.50) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL162674 0.83 GABRP (0.50) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL12681822 0.81 ALOX15 (0.51) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL17992239 0.81 GABRP (0.49) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL2544551 0.81 CREBBP (0.51) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL15287084 0.81 GABRP (0.49) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL3728572 0.81 GABRP (0.49) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL4674699 0.80 BAZ2B (0.53) GABRPGABRDGABRA1GABRB1GABRG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12331046-B2 CTPS1 inhibitors and uses thereof NIMBUS CLOTHO, INC. (US) 2025-06-17 — — US disclosed
US-12188139-B2 Alternating current electrolysis for use in organic synthesis WAYNE STATE UNIVERSITY (US) 2025-01-07 — — US disclosed
CN-119212699-A NLRP3 inhibitors PTC医疗公司 2024-12-27 — — CN disclosed
EP-4479045-A2 INHIBITORS OF NLRP3 PTC Therapeutics, Inc. (US) 2024-12-25 — — EP disclosed
WO-2024255697-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND MEDICAL USE THEREOF 中国医药研究开发中心有限公司 2024-12-19 — — WO disclosed
US-20240262806-A1 INHIBITORS OF NLRP3 PCT THERAPEUTICS, INC. (US) 2024-08-08 — — US disclosed
CN-118302417-A NLRP3 inhibitors PTC医疗公司 2024-07-05 — — CN disclosed
EP-4392414-A1 INHIBITORS OF NLRP3 PTC Therapeutics, Inc. (US) 2024-07-03 — — EP disclosed
WO-2024105563-A1 SUBSTITUTED BICYCLIC PYRIDONE DERIVATIVES PFIZER INC. (US) 2024-05-23 — — WO disclosed
CN-115403584-B 2-thio-2, 3-dihydropyrimidine-4-one derivatives, pharmaceutical compositions, preparation methods and applications thereof 长春金赛药业有限责任公司 2024-04-02 — — CN disclosed
EP-1255752-A2 PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS Sugen, Inc. (US) 2002-11-13 — — EP disclosed
US-20020156292-A1 Pyrrole substituted 2-indolinone protein kinase inhibitors PHARMACIA & UPJOHN COMPANY LLC 2002-10-24 — — US disclosed
WO-2002081466-A1 PRODRUGS OF 3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES SUGEN, INC. (US) 2002-10-17 — — WO disclosed
EP-1244672-A1 4-SUBSTITUTED 7-AZA-INDOLIN-2-ONES AND THEIR USE AS PROTEIN KINASE INHIBITORS Sugen, Inc. (US) 2002-10-02 — — EP disclosed
WO-2002055517-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES CUI JINGRONG (US) 2002-07-18 — — WO disclosed
EP-1139754-A1 3-HETEROARYLIDENYL-2-INDOLINONE COMPOUNDS FOR MODULATING PROTEIN KINASE ACTIVITY AND FOR USE IN CANCER CHEMOTHERAPY Sugen, Inc. (US) 2001-10-10 — — EP disclosed
WO-2001060814-A2 PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS SUGEN, INC. (US) 2001-08-23 — — WO disclosed
WO-2001049287-A1 3-HETEROARYLIDENYL-2-INDOLINONE COMPOUNDS FOR MODULATING PROTEIN KINASE ACTIVITY AND FOR USE IN CANCER CHEMOTHERAPY SUGEN, INC. (US) 2001-07-12 — — WO disclosed
WO-2001046196-A1 4-SUBSTITUTED 7-AZA-INDOLIN-2-ONES AND THEIR USE AS PROTEIN KINASE INHIBITORS SUGEN, INC. (US) 2001-06-28 — — WO disclosed
WO-2000038519-A1 3-HETEROARYLIDENYL-2-INDOLINONE COMPOUNDS FOR MODULATING PROTEIN KINASE ACTIVITY AND FOR USE IN CANCER CHEMOTHERAPY SUGEN, INC. (US) 2000-07-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240262806-A1 INHIBITORS OF NLRP3 NLRP3, NOD1, NLRP1 GABRP 1192/4885GABRD 4300/4885GABRA1 3314/4885
US-12331046-B2 CTPS1 inhibitors and uses thereof CTPS1, CTPS2, ECHS1 GABRP 4237/4885GABRD 4026/4885GABRA1 4568/4885
US-20020156292-A1 Pyrrole substituted 2-indolinone protein kinase inhibitors PDPK1, MAP3K20, PLK2 GABRP 1515/4885GABRD 3370/4885GABRA1 3692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.